Lacosamide extended release capsule- Adamas Pharmaceuticals

Drug Profile

Lacosamide extended release capsule- Adamas Pharmaceuticals

Alternative Names: ADS 4101; Lacosamide extended release capsule

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adamas Pharmaceuticals
  • Class Acetamides; Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action CRMP2 protein modulators; Glycine NMDA-associated antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 02 Nov 2017 Adamas completes a phase Ib steady-state pharmacokinetic trial in USA (PO) before November 2017
  • 07 Sep 2017 Pharmacokinetics and adverse event data from a phase Ib trial in Healthy volunteers released by Adamas
  • 22 May 2017 Adamas initiates enrolment in a multi dose phase Ia trial for Epilepsy (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top